Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent prior to any study-mandated procedure.~* Patients with PAH who completed study AC-055-401~* Women of childbearing potential must:~* Have a negative urine pregnancy test at Visit 1 and agree to perform monthly serum pregnancy tests.~* Agree to use two methods of contraception from Visit 1 until 1 month after study drug discontinuation.~Exclusion Criteria:~* Patients who prematurely discontinued study drug in study AC-055-401~* Females who are lactating or pregnant (positive Visit 1 pregnancy test) or plan to become pregnant during the study~* Known hypersensitivity to macitentan or its excipients or drugs of the same class

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Macitentan (Type: EXPERIMENTAL): Macitentan tablet, dose of 10 mg, once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).